trending Market Intelligence /marketintelligence/en/news-insights/trending/gWxPay3VSpf_8OEz8hl_1A2 content esgSubNav
In This List

Tensall Bio-Tech H1 profit climbs YOY

Blog

Gold - Geopolitical tensions and inflation remain key drivers

Blog

Lithium and Cobalt - Softer demand weighs on prices

Podcast

Street Talk | Episode 94: Recessionary fears in ’22 overblown, Fed could overtighten

Podcast

Next in Tech | Episode 65: The operations side of AI/ML


Tensall Bio-Tech H1 profit climbs YOY

Tensall Bio-Tech Co. Ltd. said its normalized net income for the first half came to 30 Taiwan cents per share, an increase from 2 cents per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was NT$9.2 million, a gain from NT$532,500 in the prior-year period.

Total revenue rose 20.7% on an annual basis to NT$99.4 million from NT$82.4 million, and total operating expenses climbed 5.5% on an annual basis to NT$84.0 million from NT$79.6 million.

Reported net income rose year over year to NT$14.7 million, or 48 cents per share, from NT$581,000, or 2 cents per share.

As of Aug. 15, US$1 was equivalent to NT$31.33.